FilingReader Intelligence
Shanghai Pharmaceuticals gains FDA approval for generics
May 20, 2025 at 05:11 PM UTC•By FilingReader AI
Shanghai Pharmaceuticals Holding (SSE:601607) has announced that its subsidiary, Changzhou Pharmaceutical Factory, received U.S. Food and Drug Administration (FDA) approval for its rivaroxaban tablets. Rivaroxaban is used to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation patients. As of the announcement, Shanghai Pharmaceuticals has invested approximately CNY8.2 million in R&D for rivaroxaban.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:601607•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime